Lactoferrin nanoparticles coencapsulated with curcumin and tenofovir improve vaginal defense against HIV-1 infection.
Nanomedicine (Lond)
; 16(7): 569-586, 2021 03.
Article
em En
| MEDLINE
| ID: mdl-33660529
ABSTRACT
Aim:
We report here the development of tenofovir- and curcumin-loaded lactoferrin nanoparticles (TCNPs) as an HIV-microbicide. Materials &methods:
TCNPs were subjected to various physicochemical characterization experiments, followed by in vitro and in vivo experiments to assess their efficacy.Results:
TCNPs had a diameter of 74.31 ± 2.56 nm with a gross encapsulation of more than 61% for each drug. Nanoparticles were effective against HIV-1 replication, with an IC50 of 1.75 µM for curcumin and 2.8 µM for tenofovir. TCNPs provided drug release at the application site for up to 8-12 h, with minimal leakage into the systemic circulation. TCNPs showed spermicidal activity at ≥200 µM and induced minimal cytotoxicity and inflammation in the vaginal epithelium as revealed by histopathological and ELISA studies.Conclusion:
We demonstrated that TCNPs could serve as a novel anti-HIV microbicidal agent in rats. [Formula see text].Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
HIV-1
/
Nanopartículas
Limite:
Animals
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article